Cytori Therapeutics Prices $20.0 Million Public Offering of Common Stock

  Cytori Therapeutics Prices $20.0 Million Public Offering of Common Stock

Business Wire

SAN DIEGO -- December 14, 2012

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced the sale of 7,020,000
shares of its common stock in an underwritten public offering at a price to
the public of $2.85 per share. The net offering proceeds to Cytori from the
sale of the shares are expected to be approximately $18.5 million, after
deducting underwriting discounts and commissions and other estimated offering
expenses, but excluding any exercise of the underwriters’ over-allotment

Cytori anticipates using the net proceeds from this offering for general
corporate purposes, including the continued development, manufacture,
marketing and sale of its Celution System family of products, including
related research and clinical trials, and other related research and
development, sales and marketing, and general administrative expenses, working
capital, capital expenditures and future acquisitions.

The offering is expected to close on or about December 19, 2012, subject to
customary closing conditions. In addition, Cytori has granted the underwriters
a 30-day option to purchase up to an additional 1,053,000 shares of common
stock on the same terms and conditions, solely to cover over-allotments, if

Lazard Capital Markets LLC is acting as the sole book-running manager of the
offering. Maxim Group, LLC and Ascendiant Capital Markets, LLC are each acting
as co-managers for the offering.

The shares described above will be issued pursuant to a prospectus supplement
filed as part of a shelf registration statement on Form S-3 previously filed
with and declared effective by the Securities and Exchange Commission (“SEC”).
The offering may be made only by means of a prospectus supplement and the
accompanying prospectus, copies of which may be obtained by sending a request
to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or
via telephone at (800) 542-0970. Cytori intends to file a final prospectus
supplement relating to the offering with the SEC, which will be available
along with the accompanying prospectus filed with the SEC in connection with
the shelf registration, on the SEC’s website at

This press release does not constitute an offer to sell or a solicitation of
an offer to buy any securities of Cytori, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press release is being
issued pursuant to and in accordance with Rule 134 under the Securities Act of
1933, as amended.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
repair soft tissue defects. Cytori’s scientific data suggest ADRCs improve
blood flow, moderate the immune response and keep tissue at risk of dying
alive. As a result, Cytori believes these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution® system product family.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect Cytori’s future operating
results and financial position. Such statements, including, but not limited
to, those regarding statements about Cytori’s expectations regarding its
fundraising efforts, including the closing of the public offering, the
anticipated use of proceeds from the offering and the underwriter’s exercise
of its over-allotment option, involve known and unknown risks that relate to
Cytori’s future events or future financial performance and the actual results
could differ materially from those discussed in this communication. Risks and
uncertainties that may cause Cytori's actual results to differ materially from
those discussed in this communication can be found in the "Risk Factors"
section of Cytori's Form 10-K, Forms 10-Q and its other filings with the
Securities and Exchange Commission. Readers are cautioned not to place undue
reliance on these forward-looking statements that speak only as of the date
hereof, and Cytori assumes no responsibility to update or revise any
forward-looking statements contained in this communication to reflect events,
trends or circumstances after the date of this communication.


Cytori Therapeutics, Inc.
Tom Baker, +1-858-875-5258
Megan McCormick, +1-858-875-5279
Press spacebar to pause and continue. Press esc to stop.